Provide feedbackProvide feedback

Home :: Endocrinology

Voxiva partners with Gateway Health to provide diabetes support program via mobile phone

Wednesday, May 22 2013 | Comments
Evidence Grade 0 What's This?

Members of Gateway Health, a managed care organization, will be able to enroll in a new personalized diabetes self-management program developed by Voxiva Inc. that will be delivered to patients' mobile phones. The program, known as Care4Life, uses text messages, a personal web portal, and mobile website to connect, engage, and support people with diabetes. Voxiva explained that Care4Life combines diabetes education with evidence-based behavior change techniques. Gateway Health, which...

Members of Gateway Health, a managed care organization, will be able to enroll in a new personalized diabetes self-management program developed by Voxiva Inc. that will be delivered to patients' mobile phones.

The program, known as Care4Life, uses text messages, a personal web portal, and mobile website to connect, engage, and support people with diabetes. Voxiva explained that Care4Life combines diabetes education with evidence-based behavior change techniques.

Gateway Health, which provides health care to Medicaid and Medicare members, serves nearly 300,000 of Pennsylvania's at-risk and most vulnerable patients.

Latest News

Oramed's IND for oral insulin capsule granted FDA clearance Verusmed

Wednesday, May 22 2013 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration approved Oramed Pharmaceuticals Inc.'s Investigational New Drug application for ORMD-0801, an orally ingestible insulin capsule.

The firm will begin studies of ORMD-0801 for the treatment of early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the...



Merck, Abide Therapeutics to collaborate on treatments for type 2 diabetes, metabolic diseases Verusmed

Wednesday, May 22 2013 | Comments
Evidence Grade 0 What's This?

Merck and Abide Therapeutics Inc. agreed to jointly discover, develop, and market small molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

Under the terms of the agreement, Abide Therapeutics is eligible to receive an...



Impaired FPG, type 2 diabetes represent risk factors for sudden cardiac death, all-cause mortality, study reveals Verusmed

Wednesday, May 22 2013 | Comments
Evidence Grade 0 What's This?

Men who have impaired fasting plasma glucose (FPG), regardless of whether or not they have type 2 diabetes, appear to have an increased risk of out-of-hospital sudden cardiac death (SCD), according to recent data.

A team of researchers investigated risk predictors for atherosclerotic cardiovascular outcomes in a population-based sample of men from eastern Finland. The prospective study involved 2,641 men aged 42 to 60 years who were followed up for an average of 18.8 years.

Metformin may not boost breast cancer survival among older women with diabetes, new research reveals Verusmed

Wednesday, May 22 2013 | Comments
Evidence Grade 0 What's This?

Use of metformin does not appear to improve survival rates among older women with incident diabetes and breast cancer, according to a new study.

Using administrative health care databases in Ontario, Canada, researchers conducted a population-based study of 2,361 women aged >=66 years with recent-onset diabetes who received a breast cancer diagnosis between April 1, 1997, and March 31, 2008. The women were followed through death or March 30, 2010, whichever came first. Mean...

Tags: Breast Cancer




  1. No articles have been read
  1. No articles have been emailed
Videos